Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 52

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Study on the Effects of Sonelokimab for Patients with Moderate-to-Severe Palmoplantar Pustulosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Effectiveness and Safety of Danicopan for Adults with Chronic Spontaneous Urticaria Resistant to H1-Antihistamines

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Major depression

Not recruiting

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nelivaptan
  • Sponsor:HMNC Holding GmbH

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Fasudil Hydrochloride for Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fasudil Hydrochloride
  • Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Dermatitis atopic

Not recruiting

Long-Term Safety Study of Dupilumab for Children and Teens with Atopic Dermatitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.